Amphastar Pharmaceuticals reports Q2 net revenues of $174.4 million and net income of $31.0 million

Reuters11-21
<a href="https://laohu8.com/S/AMPH">Amphastar Pharmaceuticals</a> reports <a href="https://laohu8.com/S/QTWO">Q2</a> net revenues of $174.4 million and net income of $31.0 million

Amphastar Pharmaceuticals Inc. reported net product revenues of $174.4 million for the three months ended June 30, 2025, compared to $179.4 million for the same period in 2024. Total net revenues for the quarter were $174.4 million, down from $182.4 million in the prior year period. Gross profit was $86.5 million, compared to $95.2 million for the second quarter of 2024. For the six months ended June 30, 2025, net product revenues were $344.9 million, compared to $337.0 million for the same period in 2024, while total net revenues were $344.9 million, down from $354.2 million. Cost of revenues for the quarter was $87.9 million, compared to $87.2 million a year earlier. Operating expenses for the quarter included $10.2 million in selling, distribution, and marketing, $14.0 million in general and administrative, and $20.1 million in research and development. The company noted there is no guarantee that its sales strategies will be successful or that significant sales of BAQSIMI will continue.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amphastar Pharmaceuticals Inc. published the original content used to generate this news brief on November 20, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment